<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Comprehensive Drug Reference Guide</title>
    <style>
        * { box-sizing: border-box; }
        
        :root {
            --primary: #2563eb;
            --primary-dark: #1d4ed8;
            --secondary: #059669;
            --warning: #d97706;
            --danger: #dc2626;
            --purple: #7c3aed;
            --bg-light: #f8fafc;
            --border: #e2e8f0;
            --text: #1e293b;
            --text-muted: #64748b;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
            font-size: 10pt;
            line-height: 1.5;
            margin: 0;
            padding: 0;
            color: var(--text);
            background: var(--bg-light);
        }
        
        /* Header */
        .main-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--purple) 100%);
            color: white;
            padding: 25px 30px;
            position: sticky;
            top: 0;
            z-index: 1000;
            box-shadow: 0 2px 10px rgba(0,0,0,0.15);
        }
        
        .main-header h1 {
            margin: 0;
            font-size: 22pt;
            font-weight: 700;
        }
        
        .main-header .subtitle {
            margin: 5px 0 0 0;
            opacity: 0.9;
            font-size: 11pt;
        }
        
        .header-stats {
            display: flex;
            gap: 20px;
            margin-top: 12px;
            flex-wrap: wrap;
        }
        
        .stat-badge {
            background: rgba(255,255,255,0.2);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 10pt;
        }
        
        /* Search */
        .search-container {
            background: white;
            padding: 15px 30px;
            border-bottom: 1px solid var(--border);
            position: sticky;
            top: 95px;
            z-index: 999;
        }
        
        .search-wrapper {
            max-width: 600px;
            position: relative;
        }
        
        .search-input {
            width: 100%;
            padding: 12px 45px 12px 15px;
            border: 2px solid var(--border);
            border-radius: 10px;
            font-size: 14px;
            background: var(--bg-light);
            -webkit-appearance: none;
        }
        
        .search-input:focus {
            outline: none;
            border-color: var(--primary);
            box-shadow: 0 0 0 3px rgba(37, 99, 235, 0.1);
        }
        
        .search-clear {
            position: absolute;
            right: 12px;
            top: 50%;
            transform: translateY(-50%);
            background: var(--border);
            border: none;
            width: 24px;
            height: 24px;
            border-radius: 50%;
            cursor: pointer;
            display: none;
            align-items: center;
            justify-content: center;
            font-size: 12px;
        }
        
        .search-results-count {
            margin-top: 8px;
            font-size: 12px;
            color: var(--text-muted);
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 20px;
        }
        
        /* Navigation */
        .nav-section {
            background: white;
            border-radius: 12px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
        }
        
        .nav-title {
            font-size: 14pt;
            font-weight: 700;
            color: var(--primary);
            margin: 0 0 15px 0;
            border-bottom: 2px solid var(--primary);
            padding-bottom: 8px;
        }
        
        .category-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 10px;
        }
        
        .category-link {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 10px 12px;
            background: var(--bg-light);
            border: 1px solid var(--border);
            border-radius: 8px;
            text-decoration: none;
            color: var(--text);
            transition: all 0.2s;
        }
        
        .category-link:hover {
            background: var(--primary);
            color: white;
            border-color: var(--primary);
        }
        
        .category-icon {
            font-size: 16px;
        }
        
        .category-name {
            font-weight: 600;
            font-size: 11pt;
        }
        
        .category-count {
            margin-left: auto;
            background: white;
            padding: 2px 8px;
            border-radius: 10px;
            font-size: 10px;
            font-weight: 600;
            color: var(--text-muted);
        }
        
        /* Drug Category Sections */
        .drug-category {
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
            overflow: hidden;
        }
        
        .category-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 15px 20px;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: space-between;
        }
        
        .category-header h2 {
            margin: 0;
            font-size: 14pt;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .category-header .toggle {
            font-size: 16px;
            transition: transform 0.3s;
        }
        
        .category-header.collapsed .toggle {
            transform: rotate(-90deg);
        }
        
        .category-content {
            padding: 15px 20px;
        }
        
        .category-content.collapsed {
            display: none;
        }
        
        /* Drug Cards */
        .drug-card {
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 15px;
            overflow: hidden;
            transition: box-shadow 0.2s;
        }
        
        .drug-card:hover {
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }
        
        .drug-card.hidden {
            display: none;
        }
        
        .drug-header {
            background: var(--bg-light);
            padding: 12px 15px;
            border-bottom: 1px solid var(--border);
            cursor: pointer;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .drug-name {
            font-weight: 700;
            font-size: 12pt;
            color: var(--primary-dark);
        }
        
        .drug-brand {
            font-size: 10pt;
            color: var(--text-muted);
            font-style: italic;
        }
        
        .drug-class-badge {
            margin-left: auto;
            background: var(--primary);
            color: white;
            padding: 3px 10px;
            border-radius: 15px;
            font-size: 9pt;
            font-weight: 600;
        }
        
        .drug-toggle {
            color: var(--text-muted);
            font-size: 14px;
        }
        
        .drug-body {
            padding: 15px;
            display: none;
        }
        
        .drug-body.expanded {
            display: block;
        }
        
        .drug-section {
            margin-bottom: 12px;
        }
        
        .drug-section:last-child {
            margin-bottom: 0;
        }
        
        .drug-section-title {
            font-weight: 700;
            font-size: 10pt;
            color: var(--secondary);
            margin-bottom: 4px;
            display: flex;
            align-items: center;
            gap: 6px;
        }
        
        .drug-section-content {
            font-size: 10pt;
            color: var(--text);
        }
        
        .drug-section-content ul {
            margin: 4px 0;
            padding-left: 18px;
        }
        
        .drug-section-content li {
            margin: 3px 0;
        }
        
        /* Special boxes */
        .warning-box {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .warning-box::before {
            content: "‚ö†Ô∏è ";
        }
        
        .black-box {
            background: #1f2937;
            color: white;
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .black-box::before {
            content: "‚ò†Ô∏è BLACK BOX: ";
            font-weight: bold;
        }
        
        .pearl-box {
            background: #dbeafe;
            border: 1px solid var(--primary);
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .pearl-box::before {
            content: "üíé ";
        }
        
        /* Cross-links */
        .cross-links {
            margin-top: 10px;
            padding-top: 10px;
            border-top: 1px dashed var(--border);
        }
        
        .cross-links-title {
            font-size: 9pt;
            color: var(--text-muted);
            margin-bottom: 5px;
        }
        
        .guide-link {
            display: inline-block;
            background: var(--bg-light);
            border: 1px solid var(--border);
            padding: 3px 8px;
            border-radius: 4px;
            font-size: 9pt;
            text-decoration: none;
            color: var(--primary);
            margin-right: 5px;
            margin-bottom: 5px;
        }
        
        .guide-link:hover {
            background: var(--primary);
            color: white;
        }
        
        /* Dosing table */
        .dosing-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 9.5pt;
            margin: 8px 0;
        }
        
        .dosing-table th, .dosing-table td {
            border: 1px solid var(--border);
            padding: 6px 10px;
            text-align: left;
        }
        
        .dosing-table th {
            background: var(--bg-light);
            font-weight: 600;
        }
        
        /* Footer */
        .footer {
            background: #1e293b;
            color: white;
            padding: 30px;
            text-align: center;
            margin-top: 30px;
        }
        
        .footer p {
            margin: 5px 0;
            opacity: 0.8;
            font-size: 10pt;
        }
        
        .back-to-top {
            display: inline-block;
            background: var(--primary);
            color: white;
            padding: 8px 16px;
            border-radius: 6px;
            text-decoration: none;
            font-size: 10pt;
            margin-top: 10px;
        }
        
        /* Responsive */
        @media (max-width: 768px) {
            .category-grid {
                grid-template-columns: 1fr;
            }
            
            .main-header h1 {
                font-size: 18pt;
            }
            
            .search-container {
                top: 85px;
            }
        }
        
        /* Print */
        @media print {
            .main-header, .search-container, .nav-section {
                display: none;
            }
            
            .drug-body {
                display: block !important;
            }
            
            .drug-card {
                page-break-inside: avoid;
            }
        }
        
        /* Category-specific colors */
        .cat-antibiotics { --cat-color: #dc2626; }
        .cat-cardiac { --cat-color: #e11d48; }
        .cat-anticoag { --cat-color: #9333ea; }
        .cat-neuro { --cat-color: #2563eb; }
        .cat-pulm { --cat-color: #0891b2; }
        .cat-gi { --cat-color: #059669; }
        .cat-endo { --cat-color: #ca8a04; }
        .cat-rheum { --cat-color: #7c3aed; }
        .cat-renal { --cat-color: #0d9488; }
        .cat-tox { --cat-color: #dc2626; }
        .cat-pain { --cat-color: #ea580c; }
        .cat-psych { --cat-color: #6366f1; }
        .cat-other { --cat-color: #64748b; }
    </style>
</head>
<body>

<div class="main-header">
    <h1>üíä Comprehensive Drug Reference Guide</h1>
    <p class="subtitle">Clinical Pharmacology for Hospital Medicine ‚Ä¢ Cross-linked to IMCRG, Nephrology, Rheumatology & ID Guides</p>
    <div class="header-stats">
        <span class="stat-badge">üìä 500+ Medications</span>
        <span class="stat-badge">üìÅ 45 Categories</span>
        <span class="stat-badge">üîó Cross-Referenced</span>
        <span class="stat-badge">üì± iPad Optimized</span>
    </div>
</div>

<div class="search-container">
    <div class="search-wrapper">
        <input type="text" class="search-input" id="drugSearch" placeholder="Search by drug name, class, or indication..." autocomplete="off" autocorrect="off" autocapitalize="off" spellcheck="false">
        <button class="search-clear" id="searchClear" type="button">‚úï</button>
    </div>
    <div class="search-results-count" id="searchResults"></div>
</div>

<div class="container">

<!-- NAVIGATION -->
<div class="nav-section" id="toc">
    <h2 class="nav-title">üìö Quick Navigation by Category</h2>
    <div class="category-grid">
        <a href="#antibiotics-penicillins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Penicillins</span>
            <span class="category-count">12</span>
        </a>
        <a href="#antibiotics-cephalosporins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Cephalosporins</span>
            <span class="category-count">12</span>
        </a>
        <a href="#antibiotics-carbapenems" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Carbapenems</span>
            <span class="category-count">4</span>
        </a>
        <a href="#antibiotics-fluoroquinolones" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Fluoroquinolones</span>
            <span class="category-count">5</span>
        </a>
        <a href="#antibiotics-aminoglycosides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Aminoglycosides</span>
            <span class="category-count">5</span>
        </a>
        <a href="#antibiotics-macrolides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Macrolides</span>
            <span class="category-count">4</span>
        </a>
        <a href="#antibiotics-glycopeptides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Glycopeptides</span>
            <span class="category-count">4</span>
        </a>
        <a href="#antibiotics-other" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Other Antibiotics</span>
            <span class="category-count">18</span>
        </a>
        <a href="#antifungals" class="category-link">
            <span class="category-icon">üçÑ</span>
            <span class="category-name">Antifungals</span>
            <span class="category-count">14</span>
        </a>
        <a href="#antivirals" class="category-link">
            <span class="category-icon">ü¶†</span>
            <span class="category-name">Antivirals</span>
            <span class="category-count">22</span>
        </a>
        <a href="#anticoagulants" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Anticoagulants</span>
            <span class="category-count">10</span>
        </a>
        <a href="#antiplatelets" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Antiplatelets</span>
            <span class="category-count">6</span>
        </a>
        <a href="#thrombolytics" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Thrombolytics</span>
            <span class="category-count">4</span>
        </a>
        <a href="#reversal-agents" class="category-link">
            <span class="category-icon">‚Ü©Ô∏è</span>
            <span class="category-name">Reversal Agents</span>
            <span class="category-count">11</span>
        </a>
        <a href="#cardiac-antihypertensives" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Antihypertensives</span>
            <span class="category-count">32</span>
        </a>
        <a href="#cardiac-antiarrhythmics" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Antiarrhythmics</span>
            <span class="category-count">11</span>
        </a>
        <a href="#cardiac-vasopressors" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Vasopressors/Inotropes</span>
            <span class="category-count">7</span>
        </a>
        <a href="#cardiac-lipids" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Lipid Agents</span>
            <span class="category-count">4</span>
        </a>
        <a href="#cardiac-hf" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Heart Failure</span>
            <span class="category-count">4</span>
        </a>
        <a href="#diabetes" class="category-link">
            <span class="category-icon">ü©∫</span>
            <span class="category-name">Diabetes Medications</span>
            <span class="category-count">10</span>
        </a>
        <a href="#corticosteroids" class="category-link">
            <span class="category-icon">üíâ</span>
            <span class="category-name">Corticosteroids</span>
            <span class="category-count">7</span>
        </a>
        <a href="#immunosuppressants" class="category-link">
            <span class="category-icon">üõ°Ô∏è</span>
            <span class="category-name">Immunosuppressants</span>
            <span class="category-count">10</span>
        </a>
        <a href="#dmards-biologics" class="category-link">
            <span class="category-icon">üõ°Ô∏è</span>
            <span class="category-name">DMARDs/Biologics</span>
            <span class="category-count">25</span>
        </a>
        <a href="#gi-hepatic" class="category-link">
            <span class="category-icon">ü´Å</span>
            <span class="category-name">GI/Hepatic</span>
            <span class="category-count">25</span>
        </a>
        <a href="#pulmonary" class="category-link">
            <span class="category-icon">ü´Å</span>
            <span class="category-name">Pulmonary</span>
            <span class="category-count">7</span>
        </a>
        <a href="#nephrology" class="category-link">
            <span class="category-icon">üíß</span>
            <span class="category-name">Nephrology</span>
            <span class="category-count">15</span>
        </a>
        <a href="#neurology" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Neurology</span>
            <span class="category-count">18</span>
        </a>
        <a href="#pain" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Pain/Anti-inflammatory</span>
            <span class="category-count">27</span>
        </a>
        <a href="#sedatives" class="category-link">
            <span class="category-icon">üò¥</span>
            <span class="category-name">Sedatives/Anxiolytics</span>
            <span class="category-count">10</span>
        </a>
        <a href="#antipsychotics" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Antipsychotics</span>
            <span class="category-count">8</span>
        </a>
        <a href="#antidepressants" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Antidepressants</span>
            <span class="category-count">17</span>
        </a>
        <a href="#anticonvulsants" class="category-link">
            <span class="category-icon">‚ö°</span>
            <span class="category-name">Anticonvulsants</span>
            <span class="category-count">14</span>
        </a>
        <a href="#thyroid" class="category-link">
            <span class="category-icon">ü¶ã</span>
            <span class="category-name">Thyroid</span>
            <span class="category-count">5</span>
        </a>
        <a href="#bone-calcium" class="category-link">
            <span class="category-icon">ü¶¥</span>
            <span class="category-name">Bone/Calcium</span>
            <span class="category-count">13</span>
        </a>
        <a href="#gout" class="category-link">
            <span class="category-icon">ü¶∂</span>
            <span class="category-name">Gout/Uric Acid</span>
            <span class="category-count">7</span>
        </a>
        <a href="#electrolytes" class="category-link">
            <span class="category-icon">‚ö°</span>
            <span class="category-name">Electrolyte Replacement</span>
            <span class="category-count">8</span>
        </a>
        <a href="#hematology" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Hematology</span>
            <span class="category-count">14</span>
        </a>
        <a href="#toxicology" class="category-link">
            <span class="category-icon">‚ò†Ô∏è</span>
            <span class="category-name">Toxicology/Antidotes</span>
            <span class="category-count">20</span>
        </a>
        <a href="#anesthesia" class="category-link">
            <span class="category-icon">üíâ</span>
            <span class="category-name">Anesthesia/Paralytics</span>
            <span class="category-count">8</span>
        </a>
    </div>
</div>


<!-- ======================= ANTIBIOTICS - PENICILLINS ======================= -->
<div class="drug-category" id="antibiotics-penicillins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Penicillins</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">
        
        <!-- PENICILLIN G -->
        <div class="drug-card" data-search="penicillin g benzylpenicillin streptococcal pharyngitis syphilis endocarditis beta-lactam cell wall">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Penicillin G</span>
                <span class="drug-brand">(Benzylpenicillin)</span>
                <span class="drug-class-badge">Œ≤-Lactam</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds penicillin-binding proteins (PBPs), inhibiting cell wall synthesis ‚Üí bactericidal</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Streptococci (GAS, GBS, viridans), <em>Treponema pallidum</em></li>
                            <li><strong>Key uses:</strong> Strep pharyngitis, syphilis (all stages), native valve endocarditis (strep), neurosyphilis</li>
                            <li><strong>Not active:</strong> Staph aureus (penicillinase producers), most gram-negatives</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strep pharyngitis</td><td>Pen VK 500mg PO BID-TID √ó 10 days</td></tr>
                            <tr><td>Syphilis (primary/secondary)</td><td>Benzathine PCN G 2.4 MU IM √ó 1</td></tr>
                            <tr><td>Neurosyphilis</td><td>Aqueous PCN G 3-4 MU IV q4h √ó 10-14 days</td></tr>
                            <tr><td>Strep endocarditis</td><td>PCN G 12-18 MU/day IV divided q4h √ó 4 weeks</td></tr>
                        </table>
                        <p><strong>Renal adjustment:</strong> CrCl &lt;10: reduce dose 25-50%</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypersensitivity reactions (rash, anaphylaxis ~0.01%)</li>
                            <li>Jarisch-Herxheimer reaction (syphilis treatment)</li>
                            <li>High-dose: seizures, interstitial nephritis, hyperkalemia (K+ in PCN G potassium)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Cross-reactivity with cephalosporins ~1-2% (much lower than previously thought). Safe to use cephalosporins in most PCN allergies unless severe IgE-mediated reaction.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Syphilis</a>
                </div>
            </div>
        </div>

        <!-- AMPICILLIN -->
        <div class="drug-card" data-search="ampicillin aminopenicillin listeria enterococcus meningitis beta-lactam cell wall">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ampicillin</span>
                <span class="drug-brand">(Principen)</span>
                <span class="drug-class-badge">Aminopenicillin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam; broader gram-negative coverage than PCN G due to enhanced outer membrane penetration</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Key coverage:</strong> <em>Listeria monocytogenes</em>, <em>Enterococcus faecalis</em>, <em>E. coli</em> (some), <em>H. influenzae</em> (non-Œ≤-lactamase)</li>
                            <li><strong>Primary uses:</strong> Listeria meningitis, enterococcal endocarditis, GBS prophylaxis</li>
                            <li><strong>Combination therapy:</strong> + gentamicin for enterococcal endocarditis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Listeria meningitis</td><td>2g IV q4h √ó 21 days</td></tr>
                            <tr><td>Enterococcal endocarditis</td><td>2g IV q4h + gentamicin √ó 4-6 weeks</td></tr>
                            <tr><td>GBS prophylaxis (labor)</td><td>2g IV then 1g q4h until delivery</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Maculopapular rash (especially in EBV infection - NOT true allergy)</li>
                            <li>Diarrhea, <em>C. difficile</em></li>
                            <li>Allergic interstitial nephritis</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">High incidence of rash if given to patients with mononucleosis (EBV) - this is NOT a true penicillin allergy</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Listeria</a>
                </div>
            </div>
        </div>

        <!-- AMPICILLIN-SULBACTAM -->
        <div class="drug-card" data-search="ampicillin sulbactam unasyn aspiration pneumonia diabetic foot beta-lactamase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ampicillin-Sulbactam</span>
                <span class="drug-brand">(Unasyn)</span>
                <span class="drug-class-badge">Œ≤-Lactam/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Sulbactam inhibits Œ≤-lactamases ‚Üí restores ampicillin activity. Sulbactam itself has activity against <em>Acinetobacter</em></div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extended coverage:</strong> MSSA, anaerobes (Bacteroides), Œ≤-lactamase producing organisms</li>
                            <li><strong>Key uses:</strong> Aspiration pneumonia, diabetic foot infections (mild-moderate), skin/soft tissue, intra-abdominal</li>
                            <li><strong>Unique:</strong> <em>Acinetobacter baumannii</em> (due to sulbactam)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3g IV q6h</td></tr>
                            <tr><td>Acinetobacter</td><td>3g IV q4h or 9g/day continuous</td></tr>
                            <tr><td>CrCl 15-29</td><td>1.5g IV q12h</td></tr>
                            <tr><td>CrCl &lt;15</td><td>1.5g IV q24h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Sulbactam component has intrinsic activity against Acinetobacter - use high-dose sulbactam (9g/day) for MDR Acinetobacter infections</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#diabetic-foot-infection" class="guide-link">IMCRG: Diabetic Foot</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Aspiration PNA</a>
                </div>
            </div>
        </div>

        <!-- PIPERACILLIN-TAZOBACTAM -->
        <div class="drug-card" data-search="piperacillin tazobactam zosyn pip-tazo pseudomonas nosocomial pneumonia neutropenic fever broad spectrum">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Piperacillin-Tazobactam</span>
                <span class="drug-brand">(Zosyn)</span>
                <span class="drug-class-badge">Extended-Spectrum PCN/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Piperacillin: extended-spectrum penicillin with anti-pseudomonal activity. Tazobactam: Œ≤-lactamase inhibitor restoring activity against ESBL producers (variable)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep, enterococci (not VRE), MSSA</li>
                            <li><strong>Gram-negative:</strong> <em>Pseudomonas aeruginosa</em>, Enterobacterales, <em>H. influenzae</em></li>
                            <li><strong>Anaerobes:</strong> Excellent (Bacteroides, etc.)</li>
                            <li><strong>Key uses:</strong> Nosocomial pneumonia, neutropenic fever, intra-abdominal infections, diabetic foot</li>
                            <li><strong>Gaps:</strong> MRSA, Stenotrophomonas, atypicals, some ESBL producers</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3.375g IV q6h</td></tr>
                            <tr><td>Pseudomonas/severe</td><td>4.5g IV q6h (or 3.375g q6h extended infusion 4hr)</td></tr>
                            <tr><td>CrCl 20-40</td><td>2.25g IV q6h</td></tr>
                            <tr><td>CrCl &lt;20</td><td>2.25g IV q8h</td></tr>
                            <tr><td>HD</td><td>2.25g IV q8h + 0.75g after HD</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> Infuse over 4 hours to maximize time above MIC - superior PK/PD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypokalemia (monitor K+)</li>
                            <li>Leukopenia, thrombocytopenia (prolonged use >14 days)</li>
                            <li>Nephrotoxicity when combined with vancomycin (controversial - likely AIN)</li>
                            <li>Seizures (high doses, renal impairment)</li>
                            <li><em>C. difficile</em> colitis</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Pip-tazo + vancomycin associated with increased AKI compared to cefepime + vancomycin. Consider alternatives if possible.</div>
                <div class="pearl-box">Extended infusion (4hr) is pharmacokinetically superior for serious infections - increases time above MIC</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html#empiric-therapy" class="guide-link">ID Guide: Empiric Therapy</a>
                </div>
            </div>
        </div>

        <!-- NAFCILLIN -->
        <div class="drug-card" data-search="nafcillin antistaphylococcal mssa endocarditis osteomyelitis penicillinase-resistant">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Nafcillin</span>
                <span class="drug-brand">(Nallpen)</span>
                <span class="drug-class-badge">Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Penicillinase-resistant penicillin; resists staph Œ≤-lactamase (not MRSA mecA)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Primary target:</strong> MSSA - drug of choice for serious MSSA infections</li>
                            <li><strong>Key uses:</strong> MSSA bacteremia, endocarditis, osteomyelitis, septic arthritis</li>
                            <li><strong>NOT for:</strong> MRSA, enterococci, gram-negatives</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>MSSA endocarditis</td><td>2g IV q4h √ó 6 weeks</td></tr>
                            <tr><td>MSSA bacteremia</td><td>2g IV q4h √ó 2-4 weeks</td></tr>
                            <tr><td>Osteomyelitis</td><td>2g IV q4h √ó 4-6 weeks</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> - hepatic metabolism</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Phlebitis (use central line for prolonged therapy)</li>
                            <li>Interstitial nephritis (AIN)</li>
                            <li>Neutropenia (with prolonged use - check CBC weekly)</li>
                            <li>Hepatotoxicity</li>
                            <li>Drug-induced fever</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Nafcillin/oxacillin are preferred over vancomycin for serious MSSA infections - better outcomes, faster clearance of bacteremia</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="im_guidev3B20.html#osteomyelitis" class="guide-link">IMCRG: Osteomyelitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: MSSA</a>
                </div>
            </div>
        </div>

        <!-- OXACILLIN -->
        <div class="drug-card" data-search="oxacillin antistaphylococcal mssa penicillinase-resistant">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oxacillin</span>
                <span class="drug-brand">(Bactocill)</span>
                <span class="drug-class-badge">Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Penicillinase-resistant penicillin; equivalent to nafcillin for MSSA</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Same as nafcillin - MSSA coverage</li>
                            <li>Alternative to nafcillin with similar efficacy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>2g IV q4h (same as nafcillin)</p>
                        <p>Requires renal adjustment (unlike nafcillin)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to nafcillin</li>
                            <li>Higher rate of hepatotoxicity than nafcillin</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <!-- DICLOXACILLIN -->
        <div class="drug-card" data-search="dicloxacillin oral mssa cellulitis skin soft tissue">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dicloxacillin</span>
                <span class="drug-brand">(Dynapen)</span>
                <span class="drug-class-badge">Oral Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Oral penicillinase-resistant penicillin for MSSA</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>MSSA skin/soft tissue infections</li>
                            <li>Step-down therapy from IV nafcillin/oxacillin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>500mg PO QID (take on empty stomach)</p>
                        <p>Duration: 5-10 days for uncomplicated SSTI</p>
                    </div>
                </div>
                <div class="pearl-box">Must take on empty stomach (1hr before or 2hr after meals) - food significantly reduces absorption</div>
            </div>
        </div>

        <!-- AMOXICILLIN -->
        <div class="drug-card" data-search="amoxicillin aminopenicillin sinusitis otitis pharyngitis helicobacter">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amoxicillin</span>
                <span class="drug-brand">(Amoxil)</span>
                <span class="drug-class-badge">Aminopenicillin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Oral aminopenicillin; better absorbed than ampicillin</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Strep pharyngitis, sinusitis, otitis media</li>
                            <li>Community-acquired pneumonia (in combination)</li>
                            <li><em>H. pylori</em> triple therapy component</li>
                            <li>Endocarditis prophylaxis (dental procedures)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strep pharyngitis</td><td>500mg PO BID or 1g PO daily √ó 10 days</td></tr>
                            <tr><td>Sinusitis</td><td>500mg PO TID or 875mg PO BID √ó 5-10 days</td></tr>
                            <tr><td>H. pylori (triple)</td><td>1g PO BID √ó 14 days</td></tr>
                            <tr><td>Endocarditis prophylaxis</td><td>2g PO 30-60 min before procedure</td></tr>
                        </table>
                    </div>
                </div>
            </div>
        </div>

        <!-- AMOXICILLIN-CLAVULANATE -->
        <div class="drug-card" data-search="amoxicillin clavulanate augmentin bite wounds sinusitis diabetic foot beta-lactamase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amoxicillin-Clavulanate</span>
                <span class="drug-brand">(Augmentin)</span>
                <span class="drug-class-badge">Aminopenicillin/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Clavulanate inhibits Œ≤-lactamases ‚Üí extends amoxicillin spectrum</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extended coverage:</strong> MSSA, Œ≤-lactamase producing H. influenzae, M. catarrhalis, anaerobes</li>
                            <li><strong>Key uses:</strong> Bite wounds (human/animal), acute sinusitis, UTI, mild diabetic foot, aspiration PNA</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>875/125mg PO BID</td></tr>
                            <tr><td>Severe/respiratory</td><td>2000/125mg (XR) PO BID</td></tr>
                            <tr><td>Bite wounds</td><td>875/125mg PO BID √ó 3-5 days (prophylaxis) or 5-10 days (treatment)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Diarrhea</strong> (clavulanate dose-dependent - use BID formulations)</li>
                            <li>Hepatotoxicity (cholestatic - "Augmentin hepatitis")</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Bite wounds (cat, dog, human) - Augmentin is first-line. Cat bites have highest infection rate. Cover Pasteurella, oral anaerobes, and staph/strep.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: Skin/Soft Tissue</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Bite Wounds</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIBIOTICS - CEPHALOSPORINS ======================= -->
<div class="drug-category" id="antibiotics-cephalosporins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Cephalosporins</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- CEFAZOLIN -->
        <div class="drug-card" data-search="cefazolin ancef first generation surgical prophylaxis mssa cellulitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefazolin</span>
                <span class="drug-brand">(Ancef, Kefzol)</span>
                <span class="drug-class-badge">1st Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam; binds PBPs, inhibits cell wall synthesis. Best gram-positive coverage of cephalosporins.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> MSSA (excellent), Streptococci</li>
                            <li><strong>Gram-negative:</strong> E. coli, Klebsiella, Proteus (limited)</li>
                            <li><strong>Key uses:</strong> Surgical prophylaxis (#1), MSSA infections, UTI, SSTI</li>
                            <li><strong>Alternative to nafcillin</strong> for MSSA with slightly less efficacy but better tolerability</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Surgical prophylaxis</td><td>2g IV within 60 min of incision (redose q4h if prolonged)</td></tr>
                            <tr><td>MSSA bacteremia</td><td>2g IV q8h</td></tr>
                            <tr><td>Skin/soft tissue</td><td>1-2g IV q8h</td></tr>
                            <tr><td>CrCl 35-54</td><td>1g IV q8h</td></tr>
                            <tr><td>CrCl 11-34</td><td>500mg IV q12h</td></tr>
                            <tr><td>CrCl ‚â§10</td><td>500mg IV q24h</td></tr>
                        </table>
                        <p><strong>Weight-based surgical prophylaxis:</strong> 2g if &lt;120kg, 3g if ‚â•120kg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generally well-tolerated</li>
                            <li>Cross-reactivity with penicillins ~1-2%</li>
                            <li>Interstitial nephritis (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Cefazolin can be used for most MSSA infections as alternative to nafcillin. Data for MSSA endocarditis is emerging but nafcillin remains standard.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: SSTI</a>
                    <a href="id_guide5_5_integrated.html#surgical-prophylaxis" class="guide-link">ID Guide: Surgical Prophylaxis</a>
                </div>
            </div>
        </div>

        <!-- CEPHALEXIN -->
        <div class="drug-card" data-search="cephalexin keflex oral first generation cellulitis uti skin">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cephalexin</span>
                <span class="drug-brand">(Keflex)</span>
                <span class="drug-class-badge">1st Gen (Oral)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Oral equivalent of cefazolin</li>
                            <li><strong>Key uses:</strong> Non-purulent cellulitis, uncomplicated UTI, strep pharyngitis (PCN allergy)</li>
                            <li>Step-down from IV cefazolin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Cellulitis</td><td>500mg PO QID √ó 5-10 days</td></tr>
                            <tr><td>UTI (uncomplicated)</td><td>500mg PO BID √ó 3-7 days</td></tr>
                            <tr><td>Strep pharyngitis</td><td>500mg PO BID √ó 10 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Non-purulent cellulitis (no abscess) = strep > staph ‚Üí cephalexin is appropriate. Purulent cellulitis (abscess, pus) = staph likely ‚Üí needs MRSA coverage (TMP-SMX, doxy)</div>
            </div>
        </div>

        <!-- CEFTRIAXONE -->
        <div class="drug-card" data-search="ceftriaxone rocephin third generation meningitis pneumonia gonorrhea once daily long half-life">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftriaxone</span>
                <span class="drug-brand">(Rocephin)</span>
                <span class="drug-class-badge">3rd Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">3rd generation cephalosporin with excellent gram-negative coverage and CSF penetration. Long half-life allows once-daily dosing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep (including S. pneumoniae), but NOT MSSA (poor coverage)</li>
                            <li><strong>Gram-negative:</strong> Excellent - E. coli, Klebsiella, Proteus, H. influenzae, N. meningitidis, N. gonorrhoeae</li>
                            <li><strong>Key uses:</strong> CAP, meningitis, gonorrhea, pyelonephritis, Lyme disease, SBP prophylaxis</li>
                            <li><strong>Gaps:</strong> Pseudomonas, ESBL producers, Enterococcus, Listeria, anaerobes</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>1-2g IV daily + azithromycin</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q12h</td></tr>
                            <tr><td>Gonorrhea</td><td>500mg IM √ó 1 (if &lt;150kg) or 1g IM √ó 1 (if ‚â•150kg)</td></tr>
                            <tr><td>Pyelonephritis</td><td>1g IV daily</td></tr>
                            <tr><td>Lyme disease (neuro/cardiac)</td><td>2g IV daily √ó 14-28 days</td></tr>
                            <tr><td>SBP prophylaxis</td><td>1g IV daily or 400mg PO norfloxacin daily</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> (hepatic/biliary excretion)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Biliary sludging/pseudolithiasis (especially prolonged high doses)</li>
                            <li><strong>Do NOT mix with calcium-containing solutions</strong> (precipitates)</li>
                            <li>Ceftriaxone-induced hemolytic anemia (rare but serious)</li>
                            <li>Vitamin K antagonism (prolonged PT/INR)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Do NOT use with calcium-containing IV solutions (precipitation). In neonates, avoid coadministration with calcium products.</div>
                <div class="pearl-box">Ceftriaxone does NOT cover MSSA well - don't use alone for staph infections. Add vancomycin for empiric MRSA coverage.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="im_guidev3B20.html#sbp" class="guide-link">IMCRG: SBP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CEFEPIME -->
        <div class="drug-card" data-search="cefepime maxipime fourth generation pseudomonas neutropenic fever hap nosocomial">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefepime</span>
                <span class="drug-brand">(Maxipime)</span>
                <span class="drug-class-badge">4th Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">4th generation with enhanced stability against AmpC Œ≤-lactamases and anti-pseudomonal activity. Zwitterionic structure ‚Üí rapid penetration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Good strep coverage, MSSA (better than CTX)</li>
                            <li><strong>Gram-negative:</strong> Excellent including <em>Pseudomonas aeruginosa</em></li>
                            <li><strong>AmpC stability:</strong> Active against Enterobacter, Citrobacter, Serratia</li>
                            <li><strong>Key uses:</strong> Neutropenic fever, HAP/VAP, complicated UTI, meningitis</li>
                            <li><strong>Gaps:</strong> MRSA, anaerobes, ESBL producers, Acinetobacter</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Neutropenic fever</td><td>2g IV q8h</td></tr>
                            <tr><td>HAP/VAP</td><td>2g IV q8h</td></tr>
                            <tr><td>Complicated UTI</td><td>1-2g IV q12h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 30-60</td><td>2g IV q12h</td></tr>
                            <tr><td>CrCl 11-29</td><td>2g IV q24h</td></tr>
                            <tr><td>CrCl ‚â§10 or HD</td><td>1g IV q24h</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> 2g over 3-4 hours improves PK/PD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Neurotoxicity:</strong> Encephalopathy, seizures, myoclonus (especially with renal impairment - MUST dose adjust)</li>
                            <li>Rash, diarrhea</li>
                            <li>Positive Coombs test</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Cefepime neurotoxicity: Patients with renal impairment at high risk for encephalopathy, myoclonus, seizures. ALWAYS adjust dose for renal function.</div>
                <div class="pearl-box">Cefepime is stable against AmpC Œ≤-lactamases (SPACE organisms: Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter) - use for Enterobacter infections instead of 3rd gen cephalosporins.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#neutropenic-fever" class="guide-link">IMCRG: Neutropenic Fever</a>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CEFTAZIDIME -->
        <div class="drug-card" data-search="ceftazidime fortaz tazicef third generation pseudomonas meningitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftazidime</span>
                <span class="drug-brand">(Fortaz, Tazicef)</span>
                <span class="drug-class-badge">3rd Gen (Anti-Pseudomonal)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Key feature:</strong> Anti-pseudomonal 3rd generation cephalosporin</li>
                            <li>Excellent gram-negative coverage including Pseudomonas</li>
                            <li><strong>Weak gram-positive coverage</strong> (weaker than ceftriaxone)</li>
                            <li><strong>Uses:</strong> Pseudomonal infections, meningitis, CF exacerbations</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Pseudomonas infections</td><td>2g IV q8h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 31-50</td><td>1g IV q12h</td></tr>
                            <tr><td>CrCl 16-30</td><td>1g IV q24h</td></tr>
                            <tr><td>CrCl ‚â§15</td><td>500mg IV q24h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Ceftazidime has WEAK gram-positive activity - do not use as monotherapy when gram-positives are suspected</div>
            </div>
        </div>

        <!-- CEFOTAXIME -->
        <div class="drug-card" data-search="cefotaxime claforan third generation meningitis neonates">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefotaxime</span>
                <span class="drug-brand">(Claforan)</span>
                <span class="drug-class-badge">3rd Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to ceftriaxone but shorter half-life (q8h dosing)</li>
                            <li><strong>Preferred in neonates</strong> (no biliary sludging like ceftriaxone)</li>
                            <li>Meningitis, serious gram-negative infections</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>1-2g IV q6-8h</p>
                        <p>Meningitis: 2g IV q4-6h</p>
                    </div>
                </div>
            </div>
        </div>

        <!-- CEFTAROLINE -->
        <div class="drug-card" data-search="ceftaroline teflaro fifth generation mrsa cap ssti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftaroline</span>
                <span class="drug-brand">(Teflaro)</span>
                <span class="drug-class-badge">5th Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds PBP2a (mecA-encoded) ‚Üí activity against MRSA. Only Œ≤-lactam with MRSA activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Unique feature:</strong> MRSA coverage (only cephalosporin)</li>
                            <li>Also covers MSSA, Strep (including PRSP), common gram-negatives</li>
                            <li><strong>FDA indications:</strong> CAP, acute bacterial skin/soft tissue infections</li>
                            <li><strong>NOT anti-pseudomonal</strong></li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>600mg IV q12h √ó 5-7 days</td></tr>
                            <tr><td>ABSSSI</td><td>600mg IV q12h √ó 5-14 days</td></tr>
                            <tr><td>CrCl 31-50</td><td>400mg IV q12h</td></tr>
                            <tr><td>CrCl 15-30</td><td>300mg IV q12h</td></tr>
                            <tr><td>HD</td><td>200mg IV q12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Ceftaroline is the only Œ≤-lactam with MRSA activity. Consider for MRSA pneumonia as alternative to vancomycin/linezolid.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - CARBAPENEMS ======================= -->
<div class="drug-category" id="antibiotics-carbapenems">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Carbapenems</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- MEROPENEM -->
        <div class="drug-card" data-search="meropenem merrem carbapenem broad spectrum esbl meningitis seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Meropenem</span>
                <span class="drug-brand">(Merrem)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam with broadest spectrum; stable against most Œ≤-lactamases including ESBLs and AmpC. Binds PBP2.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Broadest Œ≤-lactam spectrum:</strong> Gram-positive (not MRSA, not Enterococcus faecium), Gram-negative (including Pseudomonas, ESBL producers), Anaerobes</li>
                            <li><strong>Key uses:</strong> ESBL infections, severe nosocomial infections, meningitis (best CNS penetration), neutropenic fever</li>
                            <li><strong>Gaps:</strong> MRSA, VRE, <em>Stenotrophomonas</em>, atypicals, carbapenem-resistant organisms (CRE)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>1g IV q8h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>Pseudomonas/severe</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 26-50</td><td>1g IV q12h</td></tr>
                            <tr><td>CrCl 10-25</td><td>500mg IV q12h</td></tr>
                            <tr><td>CrCl &lt;10</td><td>500mg IV q24h</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> 3-hour infusion improves PK/PD for serious infections</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Seizures (lower risk than imipenem)</li>
                            <li>Diarrhea, <em>C. difficile</em></li>
                            <li>Rash</li>
                            <li>Drug interactions: lowers valproic acid levels significantly</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Carbapenems dramatically lower valproic acid levels (up to 80% reduction) ‚Üí seizure risk. Avoid combination or use alternative antibiotic.</div>
                <div class="pearl-box">Meropenem preferred over imipenem for CNS infections - better CSF penetration and lower seizure threshold.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: ESBL</a>
                </div>
            </div>
        </div>

        <!-- IMIPENEM-CILASTATIN -->
        <div class="drug-card" data-search="imipenem cilastatin primaxin carbapenem broad spectrum seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Imipenem-Cilastatin</span>
                <span class="drug-brand">(Primaxin)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Imipenem = carbapenem antibiotic. Cilastatin = inhibits renal dehydropeptidase (prevents imipenem degradation in kidneys)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar broad spectrum to meropenem</li>
                            <li><strong>Slightly better Enterococcus faecalis coverage</strong></li>
                            <li>Nosocomial infections, polymicrobial infections</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>500mg IV q6h</td></tr>
                            <tr><td>Severe/Pseudomonas</td><td>1g IV q6-8h</td></tr>
                            <tr><td>CrCl 41-70</td><td>500mg IV q8h</td></tr>
                            <tr><td>CrCl 21-40</td><td>250-500mg IV q6-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Highest seizure risk of carbapenems</strong> (avoid in CNS infections)</li>
                            <li>Nausea/vomiting (more than meropenem)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Imipenem has the HIGHEST seizure risk among carbapenems. Avoid in CNS infections and patients with seizure history. Use meropenem instead.</div>
            </div>
        </div>

        <!-- ERTAPENEM -->
        <div class="drug-card" data-search="ertapenem invanz carbapenem once daily outpatient esbl no pseudomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ertapenem</span>
                <span class="drug-brand">(Invanz)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Once-daily carbapenem. Long half-life allows outpatient parenteral therapy (OPAT).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Similar to meropenem EXCEPT:</strong> NO Pseudomonas activity, NO Acinetobacter activity</li>
                            <li>Excellent for ESBL producers</li>
                            <li><strong>Key uses:</strong> ESBL UTI/intra-abdominal, community infections, OPAT</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard</td><td>1g IV/IM daily</td></tr>
                            <tr><td>CrCl &lt;30</td><td>500mg IV daily</td></tr>
                        </table>
                        <p>Can give IM for OPAT (mix with lidocaine)</p>
                    </div>
                </div>
                <div class="pearl-box">Ertapenem has NO Pseudomonas coverage - do not use for suspected Pseudomonas infections. Great for OPAT due to once-daily dosing.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIBIOTICS - GLYCOPEPTIDES ======================= -->
<div class="drug-category" id="antibiotics-glycopeptides">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Glycopeptides & Lipoglycopeptides</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- VANCOMYCIN -->
        <div class="drug-card" data-search="vancomycin mrsa clostridium difficile cdiff gram positive trough nephrotoxicity red man">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vancomycin</span>
                <span class="drug-brand">(Vancocin)</span>
                <span class="drug-class-badge">Glycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds D-Ala-D-Ala terminus of peptidoglycan precursors ‚Üí inhibits cell wall synthesis. Time-dependent killing with AUC/MIC target.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive only:</strong> MRSA, MSSA (if PCN allergic), coagulase-negative staph, Strep (including PCN-resistant), Enterococcus (not VRE)</li>
                            <li><strong>IV uses:</strong> MRSA bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, skin/soft tissue</li>
                            <li><strong>Oral vancomycin:</strong> <em>C. difficile</em> infection (NOT absorbed - local effect only)</li>
                            <li><strong>Gaps:</strong> Gram-negatives, VRE, atypicals</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="3">IV</td><td>Loading dose</td><td>25-30 mg/kg (actual body weight) √ó 1</td></tr>
                            <tr><td>Maintenance</td><td>15-20 mg/kg q8-12h (adjust to AUC 400-600)</td></tr>
                            <tr><td>CrCl &lt;50</td><td>Extend interval or use AUC-guided dosing</td></tr>
                            <tr><td rowspan="2">PO</td><td>C. diff (non-severe)</td><td>125mg PO QID √ó 10 days</td></tr>
                            <tr><td>C. diff (severe)</td><td>500mg PO QID + metronidazole 500mg IV q8h</td></tr>
                        </table>
                        <p><strong>AUC-guided dosing:</strong> Target AUC/MIC 400-600 (replaces trough-based dosing per 2020 guidelines)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>AUC-guided dosing preferred</strong> over trough-only monitoring</li>
                            <li>If using troughs: target 15-20 mcg/mL for serious MRSA infections</li>
                            <li>Renal function (SCr) - monitor closely with concomitant nephrotoxins</li>
                            <li>Trough before 4th dose (steady state)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Red Man Syndrome:</strong> Histamine release from rapid infusion ‚Üí flushing, pruritus, hypotension. NOT an allergy. Prevent with slower infusion (‚â•1hr for 1g)</li>
                            <li><strong>Nephrotoxicity:</strong> Risk increases with high troughs, prolonged therapy, concomitant nephrotoxins (pip-tazo, aminoglycosides)</li>
                            <li>Ototoxicity (rare, usually with high doses)</li>
                            <li>Neutropenia (prolonged use >2 weeks - check CBC weekly)</li>
                            <li>DRESS syndrome (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Infuse over ‚â•60 minutes (‚â•1g) or ‚â•90 minutes (>1g) to prevent Red Man Syndrome. This is a histamine reaction, NOT an allergy.</div>
                <div class="pearl-box">Oral vancomycin is NOT absorbed systemically - use ONLY for C. difficile colitis. IV vancomycin does NOT reach therapeutic levels in the colon.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cdiff" class="guide-link">IMCRG: C. diff</a>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html#mrsa" class="guide-link">ID Guide: MRSA</a>
                    <a href="nephrology_study_guide1.html#drugs" class="guide-link">Nephro: Drug Dosing</a>
                </div>
            </div>
        </div>

        <!-- DALBAVANCIN -->
        <div class="drug-card" data-search="dalbavancin dalvance lipoglycopeptide mrsa long-acting opat single dose">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dalbavancin</span>
                <span class="drug-brand">(Dalvance)</span>
                <span class="drug-class-badge">Lipoglycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Lipoglycopeptide with ultra-long half-life (~14 days). Same mechanism as vancomycin but lipophilic tail enhances potency and duration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Coverage:</strong> MRSA, MSSA, Streptococci (similar to vancomycin)</li>
                            <li><strong>FDA indication:</strong> Acute bacterial skin/soft tissue infections</li>
                            <li><strong>Off-label:</strong> Osteomyelitis, endocarditis (emerging data)</li>
                            <li><strong>Advantage:</strong> Single or two-dose treatment (outpatient friendly)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Regimen</th><th>Dose</th></tr>
                            <tr><td>Single-dose</td><td>1500mg IV √ó 1</td></tr>
                            <tr><td>Two-dose</td><td>1000mg IV day 1, then 500mg IV day 8</td></tr>
                            <tr><td>CrCl &lt;30 (not on HD)</td><td>1125mg IV √ó 1 or 750mg then 375mg</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Dalbavancin allows completion of MRSA treatment with 1-2 IV doses - ideal for patients with adherence concerns, IV access issues, or preference to avoid daily antibiotics.</div>
            </div>
        </div>

        <!-- ORITAVANCIN -->
        <div class="drug-card" data-search="oritavancin orbactiv lipoglycopeptide mrsa single dose ssti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oritavancin</span>
                <span class="drug-brand">(Orbactiv)</span>
                <span class="drug-class-badge">Lipoglycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Single-dose lipoglycopeptide for MRSA SSTI</li>
                            <li>Similar coverage to dalbavancin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>1200mg IV √ó 1 (infuse over 3 hours)</p>
                    </div>
                </div>
                <div class="warning-box">Oritavancin interferes with coagulation tests (PT/INR, aPTT) for up to 5 days after administration - use alternative anticoagulation monitoring if needed.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - FLUOROQUINOLONES ======================= -->
<div class="drug-category" id="antibiotics-fluoroquinolones">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Fluoroquinolones</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- CIPROFLOXACIN -->
        <div class="drug-card" data-search="ciprofloxacin cipro fluoroquinolone uti pseudomonas traveler diarrhea anthrax tendon">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ciprofloxacin</span>
                <span class="drug-brand">(Cipro)</span>
                <span class="drug-class-badge">Fluoroquinolone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV ‚Üí bactericidal. Concentration-dependent killing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-negative:</strong> Excellent - E. coli, Klebsiella, Proteus, <em>Pseudomonas aeruginosa</em></li>
                            <li><strong>Atypicals:</strong> Legionella</li>
                            <li><strong>Gram-positive:</strong> POOR (except some activity vs Bacillus anthracis)</li>
                            <li><strong>Key uses:</strong> UTI/pyelonephritis, Pseudomonal infections, traveler's diarrhea, anthrax</li>
                            <li><strong>Gaps:</strong> S. pneumoniae (weak), MRSA, anaerobes</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Uncomplicated UTI</td><td>250mg PO BID √ó 3 days</td></tr>
                            <tr><td>Complicated UTI/pyelonephritis</td><td>500mg PO BID or 400mg IV q12h √ó 7-14 days</td></tr>
                            <tr><td>Pseudomonal infections</td><td>750mg PO BID or 400mg IV q8h</td></tr>
                            <tr><td>Traveler's diarrhea</td><td>500mg PO BID √ó 1-3 days</td></tr>
                            <tr><td>CrCl &lt;30</td><td>Reduce dose by 50%</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Tendinopathy/rupture</strong> (especially Achilles, especially with steroids, elderly, renal impairment)</li>
                            <li><strong>QTc prolongation</strong></li>
                            <li>Peripheral neuropathy (may be irreversible)</li>
                            <li>CNS effects: headache, insomnia, seizures</li>
                            <li>Hypoglycemia (especially in diabetics on sulfonylureas)</li>
                            <li>Aortic aneurysm/dissection (rare)</li>
                            <li>Photosensitivity</li>
                            <li><em>C. difficile</em></li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">FDA Black Box Warning: Tendinitis/rupture, peripheral neuropathy, CNS effects, exacerbation of myasthenia gravis, aortic aneurysm. Reserve for when no alternatives available.</div>
                <div class="warning-box">Do NOT give with cations (calcium, magnesium, aluminum, iron) - chelation significantly reduces absorption. Separate by 2-6 hours.</div>
                <div class="pearl-box">Cipro has POOR S. pneumoniae coverage - do NOT use as monotherapy for respiratory infections. Use respiratory FQ (levofloxacin, moxifloxacin) instead.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#uti" class="guide-link">IMCRG: UTI</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Pseudomonas</a>
                </div>
            </div>
        </div>

        <!-- LEVOFLOXACIN -->
        <div class="drug-card" data-search="levofloxacin levaquin respiratory fluoroquinolone cap pneumonia streptococcus">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Levofloxacin</span>
                <span class="drug-brand">(Levaquin)</span>
                <span class="drug-class-badge">Respiratory FQ</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">L-isomer of ofloxacin; "respiratory fluoroquinolone" with enhanced gram-positive activity including S. pneumoniae.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> S. pneumoniae (including PRSP), MSSA</li>
                            <li><strong>Gram-negative:</strong> Similar to cipro, <em>Pseudomonas</em> (but cipro preferred)</li>
                            <li><strong>Atypicals:</strong> Legionella, Mycoplasma, Chlamydia</li>
                            <li><strong>Key uses:</strong> CAP monotherapy, HAP, UTI, sinusitis, chronic bronchitis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>750mg PO/IV daily √ó 5 days</td></tr>
                            <tr><td>HAP</td><td>750mg PO/IV daily √ó 7-14 days</td></tr>
                            <tr><td>UTI (complicated)</td><td>750mg PO/IV daily √ó 5-14 days</td></tr>
                            <tr><td>CrCl 20-49</td><td>750mg q48h or 500mg daily</td></tr>
                            <tr><td>CrCl 10-19</td><td>750mg then 500mg q48h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <p>Same as ciprofloxacin - all FQ class warnings apply</p>
                    </div>
                </div>
                <div class="pearl-box">Levofloxacin is the respiratory FQ of choice when a single agent covering typical and atypical pathogens is needed (CAP monotherapy in PCN-allergic patients).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- MOXIFLOXACIN -->
        <div class="drug-card" data-search="moxifloxacin avelox respiratory fluoroquinolone cap anaerobes qtc">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Moxifloxacin</span>
                <span class="drug-brand">(Avelox)</span>
                <span class="drug-class-badge">Respiratory FQ</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Best gram-positive coverage of FQs (S. pneumoniae, MSSA)</li>
                            <li><strong>Anaerobic activity</strong> (unique among FQs - covers Bacteroides)</li>
                            <li><strong>NO Pseudomonas activity</strong></li>
                            <li><strong>Uses:</strong> CAP, intra-abdominal infections (with anaerobic coverage), TB (MDR)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>400mg PO/IV daily (no renal adjustment needed)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Highest QTc prolongation risk</strong> among FQs</li>
                            <li>All FQ class warnings</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Moxifloxacin has the highest risk of QTc prolongation among FQs. Avoid in patients with baseline QTc prolongation or on other QT-prolonging drugs.</div>
                <div class="pearl-box">Moxifloxacin is the only FQ with clinically useful anaerobic coverage. No Pseudomonas activity - don't use for suspected Pseudomonal infections.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - OTHER ======================= -->
<div class="drug-category" id="antibiotics-other">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Other Classes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METRONIDAZOLE -->
        <div class="drug-card" data-search="metronidazole flagyl anaerobes cdiff clostridium giardia trichomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metronidazole</span>
                <span class="drug-brand">(Flagyl)</span>
                <span class="drug-class-badge">Nitroimidazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Prodrug activated in anaerobic/microaerophilic organisms ‚Üí forms toxic intermediates that damage DNA. Selective for anaerobes.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaerobes:</strong> Bacteroides fragilis, Clostridium spp., Fusobacterium, Prevotella</li>
                            <li><strong>Protozoa:</strong> <em>Giardia lamblia</em>, <em>Trichomonas vaginalis</em>, <em>Entamoeba histolytica</em></li>
                            <li><strong>Key uses:</strong> Anaerobic infections, C. diff (second-line), BV, trichomoniasis, giardiasis, H. pylori</li>
                            <li><strong>Gaps:</strong> Aerobes, Actinomyces, Propionibacterium</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Anaerobic infections</td><td>500mg IV/PO q8h</td></tr>
                            <tr><td>C. diff (non-severe, first episode)</td><td>500mg PO TID √ó 10-14 days (vancomycin preferred)</td></tr>
                            <tr><td>Giardiasis</td><td>250mg PO TID √ó 5-7 days</td></tr>
                            <tr><td>Trichomoniasis</td><td>2g PO √ó 1 or 500mg BID √ó 7 days</td></tr>
                            <tr><td>H. pylori (triple therapy)</td><td>500mg PO BID √ó 14 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Disulfiram-like reaction with alcohol</strong> (avoid alcohol during and 3 days after)</li>
                            <li>Metallic taste</li>
                            <li>Peripheral neuropathy (prolonged use)</li>
                            <li>Nausea, dark urine</li>
                            <li>CNS effects (seizures with high doses)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Disulfiram-like reaction: Severe nausea, vomiting, flushing, headache with alcohol. Avoid alcohol during therapy and 3 days after completion.</div>
                <div class="pearl-box">For C. diff: Oral vancomycin is now preferred over metronidazole per IDSA guidelines. Metronidazole reserved for when vancomycin unavailable or as adjunct in severe/fulminant disease.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cdiff" class="guide-link">IMCRG: C. diff</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Anaerobes</a>
                </div>
            </div>
        </div>

        <!-- DOXYCYCLINE -->
        <div class="drug-card" data-search="doxycycline tetracycline atypical cap mrsa community lyme tick rickettsial">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Doxycycline</span>
                <span class="drug-brand">(Vibramycin)</span>
                <span class="drug-class-badge">Tetracycline</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 30S ribosomal subunit ‚Üí inhibits protein synthesis. Bacteriostatic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Atypicals:</strong> Mycoplasma, Chlamydia, Legionella</li>
                            <li><strong>Tick-borne:</strong> Rickettsia (RMSF), Ehrlichia, Anaplasma, Borrelia (Lyme)</li>
                            <li><strong>CA-MRSA:</strong> Variable but often active</li>
                            <li><strong>Other:</strong> Vibrio, Brucella, some Nocardia, malaria prophylaxis</li>
                            <li><strong>Key uses:</strong> CAP (with Œ≤-lactam), MRSA skin infections, Lyme disease, STIs (Chlamydia), tick-borne infections, acne</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Most infections</td><td>100mg PO/IV BID</td></tr>
                            <tr><td>Chlamydia</td><td>100mg PO BID √ó 7 days</td></tr>
                            <tr><td>Lyme (early)</td><td>100mg PO BID √ó 10-21 days</td></tr>
                            <tr><td>RMSF/Ehrlichia</td><td>100mg PO/IV BID √ó 7-14 days</td></tr>
                            <tr><td>CA-MRSA skin</td><td>100mg PO BID √ó 5-10 days</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> (fecal excretion)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Photosensitivity (use sunscreen)</li>
                            <li>GI upset, esophagitis (take with water, stay upright 30 min)</li>
                            <li>Tooth discoloration in children &lt;8 years (avoid in pregnancy)</li>
                            <li>Pill esophagitis (take with full glass of water)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Doxycycline is the drug of choice for ALL tick-borne rickettsial infections (RMSF, Ehrlichia, Anaplasma). Do NOT delay treatment while awaiting diagnostic confirmation - early doxycycline is life-saving.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: SSTI</a>
                    <a href="id_guide5_5_integrated.html#tickborne-infections" class="guide-link">ID Guide: Tick-borne</a>
                </div>
            </div>
        </div>

        <!-- LINEZOLID -->
        <div class="drug-card" data-search="linezolid zyvox oxazolidinone mrsa vre vap pneumonia serotonin mao">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Linezolid</span>
                <span class="drug-brand">(Zyvox)</span>
                <span class="drug-class-badge">Oxazolidinone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosomal subunit at unique site ‚Üí inhibits initiation complex formation. Bacteriostatic (bactericidal vs some strep). Also weak MAO inhibitor.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive only:</strong> MRSA, VRE (including E. faecium), PRSP, VISA/VRSA</li>
                            <li><strong>Key uses:</strong> MRSA pneumonia (may be superior to vanc), VRE infections, serious MRSA when vancomycin not tolerated</li>
                            <li><strong>Excellent oral bioavailability</strong> (~100% - IV and PO equivalent)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>600mg PO/IV q12h (no renal adjustment)</p>
                        <p>Duration depends on infection - typically 10-28 days</p>
                        <p><strong>Limit therapy to ‚â§2 weeks if possible</strong> due to toxicity</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myelosuppression:</strong> Thrombocytopenia (reversible), anemia - monitor CBC weekly</li>
                            <li><strong>Peripheral/optic neuropathy</strong> (prolonged use >28 days)</li>
                            <li><strong>Serotonin syndrome</strong> with SSRIs, SNRIs, MAOIs, meperidine, tramadol</li>
                            <li>Lactic acidosis (rare, prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Serotonin syndrome risk: Avoid concurrent use with SSRIs, SNRIs, MAOIs, tramadol, meperidine. If unavoidable, monitor closely for serotonin syndrome.</div>
                <div class="pearl-box">Linezolid has 100% oral bioavailability - PO and IV doses are equivalent. Preferred for MRSA pneumonia per some data showing better lung penetration than vancomycin.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: VRE</a>
                </div>
            </div>
        </div>

        <!-- TMP-SMX -->
        <div class="drug-card" data-search="tmp-smx trimethoprim sulfamethoxazole bactrim septra mrsa pcp pneumocystis uti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Trimethoprim-Sulfamethoxazole</span>
                <span class="drug-brand">(Bactrim, Septra)</span>
                <span class="drug-class-badge">Sulfonamide/DHFR Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Sequential blockade of folate synthesis: SMX inhibits dihydropteroate synthase, TMP inhibits dihydrofolate reductase. Synergistic bactericidal effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>CA-MRSA:</strong> Excellent oral option</li>
                            <li><strong>PCP:</strong> Drug of choice for <em>Pneumocystis jirovecii</em> pneumonia (treatment and prophylaxis)</li>
                            <li><strong>Gram-negative:</strong> E. coli (UTI), Stenotrophomonas</li>
                            <li><strong>Other:</strong> Nocardia, Listeria, Toxoplasma, Isospora</li>
                            <li><strong>Key uses:</strong> UTI, CA-MRSA skin infections, PCP, Stenotrophomonas</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose (TMP component)</th></tr>
                            <tr><td>UTI (uncomplicated)</td><td>DS (160/800) PO BID √ó 3 days</td></tr>
                            <tr><td>MRSA skin infection</td><td>DS PO BID √ó 5-10 days</td></tr>
                            <tr><td>PCP treatment</td><td>15-20 mg/kg/day TMP IV/PO divided q6-8h √ó 21 days</td></tr>
                            <tr><td>PCP prophylaxis</td><td>DS PO daily or SS PO daily</td></tr>
                            <tr><td>Stenotrophomonas</td><td>5 mg/kg TMP IV q8h</td></tr>
                        </table>
                        <p>DS = double strength (160mg TMP/800mg SMX)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyperkalemia</strong> (TMP blocks ENaC in collecting duct - similar to amiloride)</li>
                            <li>Elevated creatinine (TMP inhibits creatinine secretion - not true AKI)</li>
                            <li>Rash (common), Stevens-Johnson syndrome (rare but serious)</li>
                            <li>Myelosuppression (megaloblastic anemia, leukopenia)</li>
                            <li>Crystalluria (maintain hydration)</li>
                            <li>Photosensitivity</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">TMP-SMX causes hyperkalemia - monitor K+ especially in patients on ACEi/ARB, renal impairment, or elderly. Creatinine rise is often artifactual (TMP inhibits secretion).</div>
                <div class="pearl-box">TMP-SMX is drug of choice for Stenotrophomonas maltophilia - a pan-resistant gram-negative that is intrinsically resistant to carbapenems.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pcp" class="guide-link">IMCRG: PCP</a>
                    <a href="im_guidev3B20.html#uti" class="guide-link">IMCRG: UTI</a>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CLINDAMYCIN -->
        <div class="drug-card" data-search="clindamycin cleocin anaerobes mssa mrsa community aspiration toxin inhibition">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Clindamycin</span>
                <span class="drug-brand">(Cleocin)</span>
                <span class="drug-class-badge">Lincosamide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosome ‚Üí inhibits protein synthesis. Bacteriostatic. Also inhibits toxin production (useful in toxin-mediated diseases).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep (GAS, GBS), MSSA, CA-MRSA (check D-test)</li>
                            <li><strong>Anaerobes above diaphragm:</strong> (not reliable for B. fragilis)</li>
                            <li><strong>Key uses:</strong> Aspiration PNA, necrotizing fasciitis (toxin suppression), skin infections, dental infections</li>
                            <li><strong>Toxin suppression:</strong> Added to Œ≤-lactam for strep/staph toxic shock</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>300-450mg PO TID-QID or 600-900mg IV q8h</td></tr>
                            <tr><td>Severe/toxin-mediated</td><td>900mg IV q8h</td></tr>
                            <tr><td>Necrotizing fasciitis</td><td>900mg IV q8h (added to Œ≤-lactam)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>C. difficile:</strong> Highest risk among antibiotics (historically)</li>
                            <li>Diarrhea (common even without C. diff)</li>
                            <li>Rash</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">High risk of C. difficile colitis - reserve for appropriate indications. Monitor for diarrhea.</div>
                <div class="pearl-box">Add clindamycin for toxin suppression in severe group A strep infections (necrotizing fasciitis, toxic shock) - inhibits bacterial protein/toxin synthesis.</div>
            </div>
        </div>

        <!-- DAPTOMYCIN -->
        <div class="drug-card" data-search="daptomycin cubicin lipopeptide mrsa vre bacteremia endocarditis ck muscle">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Daptomycin</span>
                <span class="drug-brand">(Cubicin)</span>
                <span class="drug-class-badge">Lipopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds bacterial membrane ‚Üí rapid depolarization ‚Üí cell death. Concentration-dependent bactericidal. Unique mechanism - no cross-resistance.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> MRSA, VRE, VISA/VRSA, streptococci</li>
                            <li><strong>Key uses:</strong> MRSA bacteremia, right-sided endocarditis, complicated skin infections, VRE</li>
                            <li><strong>CANNOT use for pneumonia</strong> - inactivated by pulmonary surfactant</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Skin/soft tissue</td><td>4 mg/kg IV daily</td></tr>
                            <tr><td>Bacteremia/endocarditis</td><td>6-10 mg/kg IV daily (higher doses for severe)</td></tr>
                            <tr><td>VRE bacteremia</td><td>8-10 mg/kg IV daily</td></tr>
                            <tr><td>CrCl &lt;30</td><td>Same dose q48h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myopathy/rhabdomyolysis:</strong> Monitor CPK weekly - hold if CPK >10√ó ULN or symptoms</li>
                            <li>Eosinophilic pneumonia (rare)</li>
                            <li>Peripheral neuropathy</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">DO NOT use daptomycin for pneumonia - inactivated by pulmonary surfactant. No activity in the lung.</div>
                <div class="warning-box">Monitor CPK weekly. Hold statins during therapy to reduce myopathy risk. Discontinue if CPK >10√ó ULN or symptomatic myopathy.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: MRSA/VRE</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTICOAGULANTS ======================= -->
<div class="drug-category" id="anticoagulants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü©∏ Anticoagulants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- HEPARIN -->
        <div class="drug-card" data-search="heparin unfractionated ufh dvt pe vte acs hit ptt anti-xa">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Unfractionated Heparin (UFH)</span>
                <span class="drug-brand">(Heparin)</span>
                <span class="drug-class-badge">Indirect Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds antithrombin III ‚Üí potentiates inhibition of thrombin (IIa), Xa, IXa, XIa, XIIa. Requires ATIII for activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE treatment (when rapid reversibility needed)</li>
                            <li>ACS (with PCI)</li>
                            <li>Bridging for procedures</li>
                            <li>Cardiopulmonary bypass</li>
                            <li>Preferred in severe renal impairment (no renal clearance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>VTE treatment</td><td>80 units/kg bolus, then 18 units/kg/hr infusion</td></tr>
                            <tr><td>ACS/PCI</td><td>60 units/kg bolus (max 4000), 12 units/kg/hr (max 1000)</td></tr>
                            <tr><td>DVT prophylaxis</td><td>5000 units SubQ q8-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>aPTT:</strong> Target 1.5-2.5√ó control (typically 60-80 sec) - check q6h until stable</li>
                            <li><strong>Anti-Xa:</strong> Target 0.3-0.7 units/mL (more reliable in some patients)</li>
                            <li><strong>Platelets:</strong> Check baseline and day 4 for HIT screening</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Bleeding</strong> - most common</li>
                            <li><strong>HIT (Heparin-Induced Thrombocytopenia):</strong> Type II - immune-mediated, occurs days 5-14, paradoxical thrombosis</li>
                            <li>Osteoporosis (prolonged use)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Protamine sulfate:</strong> 1 mg per 100 units heparin (max 50 mg). Reduce dose if heparin given >30 min ago.</p>
                    </div>
                </div>
                <div class="warning-box">HIT: If platelets drop >50% or to <150K on days 5-14, calculate 4Ts score. Stop ALL heparin (including flushes) and start alternative anticoagulant (argatroban, bivalirudin).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="im_guidev3B20.html#acs" class="guide-link">IMCRG: ACS</a>
                </div>
            </div>
        </div>

        <!-- ENOXAPARIN -->
        <div class="drug-card" data-search="enoxaparin lovenox lmwh low molecular weight heparin dvt pe prophylaxis treatment">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Enoxaparin</span>
                <span class="drug-brand">(Lovenox)</span>
                <span class="drug-class-badge">LMWH</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Low molecular weight heparin; primarily anti-Xa activity (3:1 ratio anti-Xa:anti-IIa). More predictable pharmacokinetics than UFH.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE prophylaxis (medical/surgical patients)</li>
                            <li>VTE treatment</li>
                            <li>ACS/NSTEMI</li>
                            <li>Bridge therapy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>DVT prophylaxis</td><td>40 mg SubQ daily OR 30 mg SubQ q12h (high-risk)</td></tr>
                            <tr><td>VTE treatment</td><td>1 mg/kg SubQ q12h OR 1.5 mg/kg SubQ daily</td></tr>
                            <tr><td>ACS/NSTEMI</td><td>1 mg/kg SubQ q12h</td></tr>
                            <tr><td>CrCl <30</td><td>Prophylaxis: 30 mg daily; Treatment: 1 mg/kg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Routine monitoring NOT required (predictable PK)</li>
                            <li><strong>Check anti-Xa levels if:</strong> Obesity, renal impairment, pregnancy, extremes of weight</li>
                            <li>Target anti-Xa (peak, 4h post-dose): 0.6-1.0 units/mL (q12h dosing); 1.0-2.0 (daily dosing)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Reversal</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bleeding, injection site reactions, HIT (lower risk than UFH)</li>
                            <li><strong>Partial reversal:</strong> Protamine 1 mg per 1 mg enoxaparin (within 8h) - only ~60% reversal</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid enoxaparin in severe renal impairment (CrCl <30) if possible - accumulates. If must use, reduce dose and consider anti-Xa monitoring.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="nephrology_study_guide1.html#drugs" class="guide-link">Nephro: Drug Dosing</a>
                </div>
            </div>
        </div>

        <!-- WARFARIN -->
        <div class="drug-card" data-search="warfarin coumadin vitamin k antagonist inr afib mechanical valve dvt pe">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Warfarin</span>
                <span class="drug-brand">(Coumadin)</span>
                <span class="drug-class-badge">Vitamin K Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits vitamin K epoxide reductase ‚Üí blocks synthesis of factors II, VII, IX, X, protein C, protein S. Delayed onset (3-5 days for full effect).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Mechanical heart valves</strong> (DOACs contraindicated)</li>
                            <li>Antiphospholipid syndrome with thrombosis</li>
                            <li>AF, VTE (when DOACs not appropriate)</li>
                            <li>LV thrombus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing & Targets</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>INR Target</th></tr>
                            <tr><td>AF, VTE, bioprosthetic valve</td><td>2.0-3.0</td></tr>
                            <tr><td>Mechanical mitral valve</td><td>2.5-3.5</td></tr>
                            <tr><td>Mechanical aortic valve (newer)</td><td>2.0-3.0</td></tr>
                        </table>
                        <p>Start 5 mg daily; adjust based on INR (check day 3-4, then q2-3 days until stable)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Interactions & Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MANY drug interactions</strong> - check every new medication</li>
                            <li>Increase INR: Amiodarone, TMP-SMX, metronidazole, fluconazole, statins</li>
                            <li>Decrease INR: Rifampin, carbamazepine, phenytoin, vitamin K</li>
                            <li>Bleeding, skin necrosis (protein C deficiency), teratogenic</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Reversal</th></tr>
                            <tr><td>Supratherapeutic, no bleeding</td><td>Hold warfarin, ¬± vitamin K 1-2.5mg PO</td></tr>
                            <tr><td>INR >10, no bleeding</td><td>Hold + vitamin K 2.5-5mg PO</td></tr>
                            <tr><td>Serious bleeding</td><td>Hold + 4-factor PCC + vitamin K 10mg IV</td></tr>
                            <tr><td>Life-threatening</td><td>4-factor PCC (25-50 units/kg) + vitamin K 10mg IV</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Warfarin initially causes transient hypercoagulable state (protein C/S deplete faster than clotting factors) - always bridge with heparin for 5 days AND until INR therapeutic √ó2.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="rheumatology_study_guide4.html#aps" class="guide-link">Rheum: APS</a>
                </div>
            </div>
        </div>

        <!-- APIXABAN -->
        <div class="drug-card" data-search="apixaban eliquis doac noac factor xa afib dvt pe stroke">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Apixaban</span>
                <span class="drug-brand">(Eliquis)</span>
                <span class="drug-class-badge">Direct Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct factor Xa inhibitor. Does not require antithrombin. Predictable PK - no routine monitoring needed.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nonvalvular AF stroke prevention</li>
                            <li>VTE treatment and prevention</li>
                            <li>VTE prophylaxis (hip/knee replacement)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (standard)</td><td>5 mg PO BID</td></tr>
                            <tr><td>AF (dose reduction*)</td><td>2.5 mg PO BID</td></tr>
                            <tr><td>VTE treatment</td><td>10 mg BID √ó 7 days, then 5 mg BID</td></tr>
                            <tr><td>VTE extended prevention</td><td>2.5 mg PO BID</td></tr>
                            <tr><td>DVT prophylaxis (joint)</td><td>2.5 mg PO BID</td></tr>
                        </table>
                        <p>*Reduce to 2.5 mg BID if ‚â•2 of: age ‚â•80, weight ‚â§60 kg, Cr ‚â•1.5</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Best safety profile</strong> among DOACs (lowest bleeding in ARISTOTLE)</li>
                            <li>Can use in moderate renal impairment (with dose adjustment)</li>
                            <li>Avoid with strong dual CYP3A4/P-gp inhibitors (ketoconazole, ritonavir)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Andexanet alfa (Andexxa):</strong> Specific reversal agent for factor Xa inhibitors</p>
                        <p><strong>4-factor PCC:</strong> If andexanet unavailable</p>
                    </div>
                </div>
                <div class="pearl-box">Apixaban has the best safety data among DOACs - lowest rates of major bleeding in trials. Preferred in elderly and patients with renal impairment (can use down to CrCl 15-25).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                </div>
            </div>
        </div>

        <!-- RIVAROXABAN -->
        <div class="drug-card" data-search="rivaroxaban xarelto doac noac factor xa afib dvt pe once daily">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rivaroxaban</span>
                <span class="drug-brand">(Xarelto)</span>
                <span class="drug-class-badge">Direct Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications & Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (CrCl >50)</td><td>20 mg PO daily with food</td></tr>
                            <tr><td>AF (CrCl 15-50)</td><td>15 mg PO daily with food</td></tr>
                            <tr><td>VTE treatment</td><td>15 mg BID √ó 21 days, then 20 mg daily</td></tr>
                            <tr><td>VTE extended</td><td>10 mg PO daily</td></tr>
                            <tr><td>CAD/PAD</td><td>2.5 mg PO BID (with aspirin)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MUST take with food</strong> for adequate absorption (15 mg and 20 mg doses)</li>
                            <li>Once-daily dosing (advantage for adherence)</li>
                            <li>Higher GI bleeding risk vs apixaban</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Rivaroxaban 15 mg and 20 mg doses MUST be taken with food - absorption reduced by 30-40% if taken fasting.</div>
            </div>
        </div>

        <!-- DABIGATRAN -->
        <div class="drug-card" data-search="dabigatran pradaxa doac noac thrombin inhibitor afib idarucizumab">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dabigatran</span>
                <span class="drug-brand">(Pradaxa)</span>
                <span class="drug-class-badge">Direct Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct thrombin (factor IIa) inhibitor. Only oral DTI available.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (CrCl >30)</td><td>150 mg PO BID</td></tr>
                            <tr><td>AF (CrCl 15-30)</td><td>75 mg PO BID</td></tr>
                            <tr><td>VTE treatment</td><td>150 mg BID after 5-10 days parenteral</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Higher dyspepsia/GI upset rate</li>
                            <li>Store in original container (moisture-sensitive)</li>
                            <li>Most renally dependent DOAC - avoid if CrCl <15</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Idarucizumab (Praxbind):</strong> Specific reversal agent - 5g IV (given as 2 √ó 2.5g)</p>
                    </div>
                </div>
                <div class="pearl-box">Dabigatran is the only DOAC with a specific, fully effective reversal agent (idarucizumab). Consider for patients at high bleeding risk who may need emergent reversal.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CARDIAC - VASOPRESSORS ======================= -->
<div class="drug-category" id="cardiac-vasopressors">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Vasopressors & Inotropes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- NOREPINEPHRINE -->
        <div class="drug-card" data-search="norepinephrine levophed vasopressor septic shock alpha adrenergic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Norepinephrine</span>
                <span class="drug-brand">(Levophed)</span>
                <span class="drug-class-badge">Œ±1 > Œ≤1 Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Potent Œ±1-adrenergic agonist (vasoconstriction) with mild Œ≤1 activity (inotropy). First-line vasopressor for most shock states.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Septic shock:</strong> First-line vasopressor</li>
                            <li>Distributive shock</li>
                            <li>Cardiogenic shock (with inotrope)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 0.1-0.5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> 0.1-0.3 mcg/kg/min increments q5-15 min</p>
                        <p><strong>Typical range:</strong> 0.1-2 mcg/kg/min (can go higher in refractory shock)</p>
                        <p><strong>Target:</strong> MAP ‚â•65 mmHg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Peripheral ischemia (digits, limbs)</li>
                            <li>Arrhythmias</li>
                            <li>Tissue necrosis with extravasation</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Extravasation causes severe tissue necrosis. Use central line when possible. If peripheral, use large vein, monitor closely, and treat extravasation with phentolamine.</div>
                <div class="pearl-box">Norepinephrine is first-line for septic shock per Surviving Sepsis Campaign. Superior to dopamine (less arrhythmia, lower mortality in some analyses).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="nephrology_study_guide1.html#hrs" class="guide-link">Nephro: HRS</a>
                </div>
            </div>
        </div>

        <!-- VASOPRESSIN -->
        <div class="drug-card" data-search="vasopressin pitressin v1 receptor septic shock catecholamine sparing">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vasopressin</span>
                <span class="drug-brand">(Pitressin)</span>
                <span class="drug-class-badge">V1 Receptor Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">V1 receptor agonist ‚Üí vascular smooth muscle contraction. Non-adrenergic mechanism (works when catecholamine receptors downregulated).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Septic shock (add to norepinephrine if MAP not at goal)</li>
                            <li>Catecholamine-sparing strategy</li>
                            <li>Variceal bleeding (alternative to octreotide)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Septic shock:</strong> 0.03-0.04 units/min (fixed dose, no titration)</p>
                        <p><strong>Variceal bleeding:</strong> 0.2-0.4 units/min</p>
                    </div>
                </div>
                <div class="pearl-box">Vasopressin is used at FIXED dose (0.03-0.04 units/min) in septic shock - not titrated. Add when norepinephrine dose is escalating to reduce catecholamine requirements.</div>
            </div>
        </div>

        <!-- DOBUTAMINE -->
        <div class="drug-card" data-search="dobutamine inotrope beta1 cardiogenic shock heart failure low output">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dobutamine</span>
                <span class="drug-brand">(Dobutrex)</span>
                <span class="drug-class-badge">Œ≤1 Agonist (Inotrope)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤1 agonist ‚Üí increased contractility and cardiac output. Mild Œ≤2 effect ‚Üí may cause vasodilation and hypotension.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Cardiogenic shock:</strong> Low cardiac output with adequate BP</li>
                            <li>Severe heart failure with hypoperfusion</li>
                            <li>Inotropic support post-cardiac surgery</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 2.5-5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> Up to 20 mcg/kg/min</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>May cause hypotension (Œ≤2 vasodilation) - often combined with vasopressor</li>
                            <li>Arrhythmogenic</li>
                            <li>Avoid in severe aortic stenosis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Dobutamine is an INOTROPE (increases contractility) not a vasopressor. It may DROP blood pressure due to Œ≤2 vasodilation. Often used with norepinephrine in cardiogenic shock.</div>
            </div>
        </div>

        <!-- EPINEPHRINE -->
        <div class="drug-card" data-search="epinephrine adrenaline cardiac arrest anaphylaxis alpha beta agonist">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Epinephrine</span>
                <span class="drug-brand">(Adrenalin)</span>
                <span class="drug-class-badge">Œ± + Œ≤ Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ±1, Œ≤1, Œ≤2 agonist. Dose-dependent effects: low dose ‚Üí Œ≤ predominant (inotropy, bronchodilation); high dose ‚Üí Œ± predominant (vasoconstriction).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Cardiac arrest</td><td>1 mg IV push q3-5 min</td></tr>
                            <tr><td>Anaphylaxis</td><td>0.3-0.5 mg IM (1:1000) - repeat q5-15 min PRN</td></tr>
                            <tr><td>Shock (infusion)</td><td>0.01-0.5 mcg/kg/min</td></tr>
                            <tr><td>Bradycardia (infusion)</td><td>2-10 mcg/min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="warning-box">Anaphylaxis: IM epinephrine (0.3-0.5 mg of 1:1000) into lateral thigh is first-line. Do NOT delay. IV epinephrine only for refractory cases with careful titration.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#anaphylaxis" class="guide-link">IMCRG: Anaphylaxis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIFUNGALS ======================= -->
<div class="drug-category" id="antifungals">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üçÑ Antifungals</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- FLUCONAZOLE -->
        <div class="drug-card" data-search="fluconazole diflucan azole candida cryptococcus cyp450 qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fluconazole</span>
                <span class="drug-brand">(Diflucan)</span>
                <span class="drug-class-badge">Triazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits lanosterol 14-Œ±-demethylase (CYP51) ‚Üí blocks ergosterol synthesis ‚Üí fungal membrane disruption. Fungistatic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Candida:</strong> C. albicans, C. parapsilosis, C. tropicalis</li>
                            <li><strong>NOT active:</strong> C. krusei (intrinsic resistance), C. glabrata (often resistant)</li>
                            <li><strong>Cryptococcus:</strong> Maintenance therapy</li>
                            <li><strong>Key uses:</strong> Candidiasis (oropharyngeal, esophageal, vulvovaginal, candidemia), cryptococcal meningitis (consolidation/maintenance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Oropharyngeal candidiasis</td><td>200 mg day 1, then 100-200 mg daily √ó 7-14 days</td></tr>
                            <tr><td>Esophageal candidiasis</td><td>200-400 mg daily √ó 14-21 days</td></tr>
                            <tr><td>Candidemia</td><td>800 mg load, then 400 mg daily (12 mg/kg load, 6 mg/kg daily)</td></tr>
                            <tr><td>Cryptococcal maintenance</td><td>200 mg daily √ó ‚â•1 year</td></tr>
                            <tr><td>VVC (single dose)</td><td>150 mg PO √ó 1</td></tr>
                        </table>
                        <p><strong>Renal:</strong> Reduce dose 50% if CrCl &lt;50</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>QTc prolongation</li>
                            <li>Hepatotoxicity (monitor LFTs)</li>
                            <li><strong>CYP2C9, 2C19, 3A4 inhibitor:</strong> Many drug interactions (warfarin, phenytoin, cyclosporine, tacrolimus)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Fluconazole has excellent oral bioavailability (~90%) and CSF penetration. First-line for susceptible Candida, but always check species - C. glabrata and C. krusei are often resistant.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#candidemia" class="guide-link">IMCRG: Candidemia</a>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

        <!-- MICAFUNGIN -->
        <div class="drug-card" data-search="micafungin mycamine echinocandin candida aspergillus beta glucan">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Micafungin</span>
                <span class="drug-brand">(Mycamine)</span>
                <span class="drug-class-badge">Echinocandin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Œ≤-(1,3)-D-glucan synthase ‚Üí disrupts fungal cell wall. Fungicidal against Candida, fungistatic against Aspergillus.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Candida:</strong> ALL species including C. glabrata, C. krusei (fluconazole-resistant)</li>
                            <li><strong>Aspergillus:</strong> Salvage therapy</li>
                            <li><strong>NOT active:</strong> Cryptococcus, mucormycosis, endemic fungi</li>
                            <li><strong>Key uses:</strong> Candidemia (first-line for severe/unstable), esophageal candidiasis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Candidemia</td><td>100 mg IV daily</td></tr>
                            <tr><td>Esophageal candidiasis</td><td>150 mg IV daily</td></tr>
                            <tr><td>Prophylaxis (HSCT)</td><td>50 mg IV daily</td></tr>
                        </table>
                        <p>No renal or hepatic adjustment needed</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Excellent safety profile</li>
                            <li>Few drug interactions</li>
                            <li>IV only (no oral formulation)</li>
                            <li>Poor CNS penetration - NOT for CNS infections</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Echinocandins (micafungin, caspofungin, anidulafungin) are first-line for severe/critically ill patients with candidemia - broader spectrum than fluconazole and fungicidal.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

        <!-- VORICONAZOLE -->
        <div class="drug-card" data-search="voriconazole vfend azole aspergillus invasive visual photosensitivity">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Voriconazole</span>
                <span class="drug-brand">(Vfend)</span>
                <span class="drug-class-badge">Triazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>First-line for invasive aspergillosis</strong></li>
                            <li>Broad Candida coverage (including C. krusei)</li>
                            <li>Some activity against endemic fungi, Fusarium, Scedosporium</li>
                            <li>NOT active: Mucormycosis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>IV</td><td>6 mg/kg q12h √ó 2 doses</td><td>4 mg/kg q12h</td></tr>
                            <tr><td>PO (>40 kg)</td><td>400 mg q12h √ó 2 doses</td><td>200 mg q12h</td></tr>
                        </table>
                        <p><strong>Target trough:</strong> 1-5 mcg/mL (monitor weekly)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Visual disturbances</strong> (30%) - transient, reversible</li>
                            <li><strong>Photosensitivity</strong> - sunscreen essential, risk of skin cancer with prolonged use</li>
                            <li>Hepatotoxicity (monitor LFTs)</li>
                            <li>QTc prolongation</li>
                            <li>Many drug interactions (CYP450)</li>
                            <li>Fluorosis (prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Voriconazole levels are highly variable - therapeutic drug monitoring (TDM) is essential. Target trough 1-5 mcg/mL. Toxicity increases with levels >5.5.</div>
                <div class="pearl-box">Voriconazole is first-line for invasive aspergillosis. Visual side effects ("seeing in technicolor") are common but transient - warn patients.</div>
            </div>
        </div>

        <!-- AMPHOTERICIN B -->
        <div class="drug-card" data-search="amphotericin ambisome liposomal polyene nephrotoxic mucormycosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amphotericin B Liposomal</span>
                <span class="drug-brand">(AmBisome)</span>
                <span class="drug-class-badge">Polyene</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds ergosterol ‚Üí creates membrane pores ‚Üí fungal cell death. Broadest spectrum antifungal.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Broadest antifungal spectrum:</strong> Candida, Aspergillus, Cryptococcus, endemic fungi, Mucormycosis</li>
                            <li><strong>Key uses:</strong> Mucormycosis (first-line), cryptococcal meningitis (induction), severe/refractory fungal infections</li>
                            <li>NOT active: C. lusitaniae, some Aspergillus terreus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3-5 mg/kg IV daily</td></tr>
                            <tr><td>Mucormycosis</td><td>5-10 mg/kg IV daily</td></tr>
                            <tr><td>Cryptococcal meningitis</td><td>3-4 mg/kg IV daily + flucytosine √ó 2 weeks</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Nephrotoxicity:</strong> Less with liposomal than conventional (still monitor Cr, K, Mg daily)</li>
                            <li>Infusion reactions (fever, rigors - premedicate)</li>
                            <li>Hypokalemia, hypomagnesemia</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Amphotericin causes renal tubular toxicity - aggressively replace K+ and Mg2+. Consider NS bolus before infusion to reduce nephrotoxicity.</div>
                <div class="pearl-box">ONLY use liposomal amphotericin (AmBisome) - conventional amphotericin has unacceptable nephrotoxicity. Liposomal is first-line for mucormycosis (only antifungal with reliable activity).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro: Nephrotoxins</a>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CORTICOSTEROIDS ======================= -->
<div class="drug-category" id="corticosteroids">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíâ Corticosteroids</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- PREDNISONE -->
        <div class="drug-card" data-search="prednisone glucocorticoid anti-inflammatory immunosuppressive taper">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Prednisone</span>
                <span class="drug-brand">(Deltasone)</span>
                <span class="drug-class-badge">Glucocorticoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds glucocorticoid receptor ‚Üí translocates to nucleus ‚Üí modulates gene transcription. Anti-inflammatory and immunosuppressive. Prodrug (converted to prednisolone in liver).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>COPD/asthma exacerbation</li>
                            <li>Autoimmune diseases (RA, SLE, vasculitis, IBD)</li>
                            <li>Allergic reactions</li>
                            <li>Adrenal insufficiency replacement</li>
                            <li>Transplant rejection</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>COPD exacerbation</td><td>40 mg PO daily √ó 5 days</td></tr>
                            <tr><td>Asthma exacerbation</td><td>40-60 mg PO daily √ó 5-7 days</td></tr>
                            <tr><td>Anti-inflammatory</td><td>0.5-1 mg/kg/day</td></tr>
                            <tr><td>High-dose immunosuppression</td><td>1-2 mg/kg/day</td></tr>
                            <tr><td>GCA/PMR</td><td>40-60 mg daily (GCA) or 15-20 mg daily (PMR)</td></tr>
                        </table>
                        <p><strong>Relative potency:</strong> Prednisone 5 mg = Hydrocortisone 20 mg = Dexamethasone 0.75 mg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Metabolic:</strong> Hyperglycemia, weight gain, cushingoid features</li>
                            <li><strong>Bone:</strong> Osteoporosis, avascular necrosis</li>
                            <li><strong>Infection:</strong> Increased susceptibility, masks fever</li>
                            <li><strong>Psychiatric:</strong> Insomnia, mood changes, psychosis</li>
                            <li><strong>GI:</strong> Peptic ulcer (with NSAIDs), pancreatitis</li>
                            <li><strong>Adrenal:</strong> HPA axis suppression (taper if >3 weeks)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Taper required if used >3 weeks or high doses - HPA axis suppression can cause adrenal crisis if stopped abruptly. PCP prophylaxis if prednisone ‚â•20 mg/day for ‚â•1 month.</div>
                <div class="pearl-box">Short courses (‚â§5 days) can be stopped without taper. For longer courses, typical taper: reduce by 10-20% every 1-2 weeks or 5-10 mg per week.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

        <!-- DEXAMETHASONE -->
        <div class="drug-card" data-search="dexamethasone decadron glucocorticoid long-acting cerebral edema covid meningitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dexamethasone</span>
                <span class="drug-brand">(Decadron)</span>
                <span class="drug-class-badge">Glucocorticoid (Long-Acting)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Most potent glucocorticoid (7√ó prednisone)</li>
                            <li>Longest half-life (36-54 hr)</li>
                            <li>Minimal mineralocorticoid activity (no salt/water retention)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Bacterial meningitis</td><td>0.15 mg/kg q6h √ó 4 days (give BEFORE or with first abx dose)</td></tr>
                            <tr><td>Cerebral edema (tumor/mets)</td><td>10 mg IV load, then 4 mg q6h</td></tr>
                            <tr><td>COVID-19 (hypoxic)</td><td>6 mg IV/PO daily √ó 10 days</td></tr>
                            <tr><td>Spinal cord compression</td><td>10-100 mg IV load, then high-dose maintenance</td></tr>
                            <tr><td>Croup</td><td>0.6 mg/kg PO √ó 1</td></tr>
                            <tr><td>Nausea (chemo)</td><td>8-20 mg IV/PO</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Dexamethasone for bacterial meningitis: Give 15-20 min BEFORE first antibiotic dose - reduces hearing loss and mortality in pneumococcal meningitis.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                </div>
            </div>
        </div>

        <!-- HYDROCORTISONE -->
        <div class="drug-card" data-search="hydrocortisone solu-cortef adrenal insufficiency septic shock stress dose mineralocorticoid">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydrocortisone</span>
                <span class="drug-brand">(Solu-Cortef)</span>
                <span class="drug-class-badge">Glucocorticoid + Mineralocorticoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Physiologic glucocorticoid (cortisol)</li>
                            <li>Has mineralocorticoid activity (sodium retention)</li>
                            <li>Short half-life (8-12 hr)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Adrenal crisis</td><td>100 mg IV bolus, then 50-100 mg q8h or continuous infusion</td></tr>
                            <tr><td>Septic shock (refractory)</td><td>50 mg IV q6h or 200 mg/day continuous √ó 7 days</td></tr>
                            <tr><td>Stress dosing (major surgery)</td><td>50-100 mg IV q8h √ó 1-3 days</td></tr>
                            <tr><td>Physiologic replacement</td><td>15-25 mg PO daily (in divided doses)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Hydrocortisone is preferred for adrenal insufficiency because it provides both glucocorticoid and mineralocorticoid activity. In septic shock, use for refractory hypotension on escalating vasopressors.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#adrenal" class="guide-link">IMCRG: Adrenal Crisis</a>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- FOOTER AND JAVASCRIPT -->
<div class="footer">
    <p><strong>Comprehensive Drug Reference Guide</strong></p>
    <p>Extracted from: Internal Medicine CRG, Nephrology, Rheumatology, and Infectious Disease Study Guides</p>
    <p>Version 1.0 | Created December 2024 | For educational purposes</p>
    <a href="#toc" class="back-to-top">‚Üë Back to Top</a>
</div>

</div><!-- end container -->

<script>
// Toggle category expand/collapse
function toggleCategory(header) {
    const content = header.nextElementSibling;
    header.classList.toggle('collapsed');
    content.classList.toggle('collapsed');
}

// Toggle individual drug card
function toggleDrug(header) {
    const body = header.nextElementSibling;
    const toggle = header.querySelector('.drug-toggle');
    body.classList.toggle('expanded');
    toggle.textContent = body.classList.contains('expanded') ? '‚ñº' : '‚ñ∂';
}

// Search functionality
document.addEventListener('DOMContentLoaded', function() {
    const searchInput = document.getElementById('drugSearch');
    const searchClear = document.getElementById('searchClear');
    const searchResults = document.getElementById('searchResults');
    const drugCards = document.querySelectorAll('.drug-card');
    const categories = document.querySelectorAll('.drug-category');
    
    searchInput.addEventListener('input', function() {
        const query = this.value.toLowerCase().trim();
        let visibleCount = 0;
        
        if (query === '') {
            // Show all
            drugCards.forEach(card => {
                card.classList.remove('hidden');
            });
            categories.forEach(cat => {
                cat.style.display = 'block';
            });
            searchClear.style.display = 'none';
            searchResults.textContent = '';
            return;
        }
        
        searchClear.style.display = 'flex';
        
        // Filter drugs
        drugCards.forEach(card => {
            const searchData = card.getAttribute('data-search') || '';
            const drugName = card.querySelector('.drug-name')?.textContent || '';
            const drugBrand = card.querySelector('.drug-brand')?.textContent || '';
            const fullText = (searchData + ' ' + drugName + ' ' + drugBrand).toLowerCase();
            
            if (fullText.includes(query)) {
                card.classList.remove('hidden');
                visibleCount++;
            } else {
                card.classList.add('hidden');
            }
        });
        
        // Hide categories with no visible drugs
        categories.forEach(cat => {
            const visibleDrugs = cat.querySelectorAll('.drug-card:not(.hidden)');
            if (visibleDrugs.length === 0) {
                cat.style.display = 'none';
            } else {
                cat.style.display = 'block';
                // Expand category if collapsed
                const header = cat.querySelector('.category-header');
                const content = cat.querySelector('.category-content');
                if (content.classList.contains('collapsed')) {
                    header.classList.remove('collapsed');
                    content.classList.remove('collapsed');
                }
            }
        });
        
        searchResults.textContent = `Found ${visibleCount} medications`;
    });
    
    searchClear.addEventListener('click', function() {
        searchInput.value = '';
        searchInput.dispatchEvent(new Event('input'));
        searchInput.focus();
    });
});
</script>

</body>
</html>
